Form 8-K - Current report:
SEC Accession No. 0001641172-25-017563
Filing Date
2025-07-02
Accepted
2025-07-02 16:14:07
Documents
15
Period of Report
2025-06-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 71057
2 EX-10.1 ex10-1.htm EX-10.1 353110
3 EX-10.2 ex10-2.htm EX-10.2 314707
4 EX-10.3 ex10-3.htm EX-10.3 205850
  Complete submission text file 0001641172-25-017563.txt   1305883

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE evfm-20250626.xsd EX-101.SCH 3008
6 XBRL LABEL FILE evfm-20250626_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE evfm-20250626_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3356
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 251101156
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)